1) Deakin JFW. Neurobiology of schizophrenia. Curr Opin Psychiatry 1996; 9: 50-6.

2) Jeste DV, Galasko D, Corey-Bloom J, Walens S, Granholm E. Neuropsychiatric aspects of the schizophrenias. En: Fogel BS, Schiffer RB, Rao SM. Neuropsychiatry. Baltimore: Williams & Wilkins, 1996; pág. 325-44.

3) Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995; 346: 743-49.

4) Halberstadt AL. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 1995; 18: 237-49.

5) Marchbanks RM, Mulcrone J, Watley SA. Aspects of oxidative metabolism in schizophrenia. Br J Psichiatry 1995; 167(3): 293-8.

6) Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980;20(3): 379-82.

7) Kim JS, Kornhuber HH, Brand U, Menge HG. Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia. Neurosci Lett 1981; 24(1): 93-6.

8) Kim JS, Claus D, Kornhuber HH. Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. Eur Neurol 1983; 22(5): 367-70.

9) Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982;231: 221-225.

10) Henn FA. The NMDA receptor as a site for psychopathology: Primary or secondary role? Arch Gen Psychiatry 1995; 52(12): 1008-10.

11) Krebs MO. Acides aminés excitateurs, une nouvelle classe de neurotransmetteurs. Pharmacologie et propiétés fonctionnelles. L’éncéphale 1992; 18: 271-9.

12) Marco-Igual M. El sistema glutamatérgico (I): aspectos moleculares, farmacológicos y funcionales. Med Clin 1995; 104(6): 34-42.

13) Zhang L, Rzigalinski BA, Ellis EF, Satin LS. Reduction of voltage-dependent Mg 2+ blockade of NMDA current in mechanically injured neurons. Science 1996; 274: 1921-3.

14) Marco-Igual M. El sistema glutamatérgico (II): aspectos fisiopatológicos, clínicos y terapéuticos. Med Clin 1995; 104(8): 34-42.

15) Lánský P, Velíšková J, Velíšek L. Extracellular pH modulates neuronal activity, neuronal plasticity and epileptic seizures. Praga: Epilepsy Research, Faculty of Medicine, Charles Univ, Praha, [three-year grant; 1995-97].

16) Urenjak J, Zilkha E, Gotoh M, Obrenovitch TP. Effect of acidotic challenges on local depolarizations evoked by N-methyl-D-aspartate in the rat striatum. Life-Sci 1997; 61(5): 523-35.

17) Aram JA, Lodge D. Epileptiform activity induced by alkalosis in rat neocortical slices: block by antagonists of N-methyl-D-aspartate. Neurosci Lett 1987; 83(3): 345-350.

18) Hurn PD, Koehler RC, Traystman RJ. Alkalemia reduces recovery from global cerebral ischemia by NMDA receptor-mediated mechanism. Am J Physiol 1997; 272(6 Pt 2): H2557-62.

19) Wu X, Christensen BN. Proton inhibition of the NMDA-gated channel in isolated catfish cone horizontal cells. Vision Res 1996; 36(11): 1521-8.

20) Trafton J, Tombaugh G, Yang S, Sapolsky R. Salutary and deleterious effects of acidity on an indirect measure of metabolic rate and ATP concentrations in CNS cultures. Brain Res 1996;731(1-2): 122-31.

21) Vornoh JJ, Thomas AG, Jo D. Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. J Nerurochem 1996; 67(6): 2379-89.

22) Ou-Yang Y, Kristian T, Mellergard P, Siesjo BK. The influence of pH on glutamate- and depolarization-induced increases of intracellular calcium concentration in cortical neurons in primary culture. Brain Res 1994; 646(1): 65-72.

23) Lee J, Taira T, Pihlaja P, Ransom BR, Kalia K. Effects of CO2 on excitatory transmission apparently caused by changes in intracellular pH in the rat hippocampal slice. Brain Res 1996; 706(2): 210-216.

24) Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, y col. Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains. Arch Gen Psychiatry 1995 Oct; 52(10): 829-36.

25) Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutama-tergic neuronal dysfunction. Neurosci Letters 1982 Jan; 28 (1): 81-5.

26) Lodge D, Anis NA. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur J Pharmacol 1982;77: 203-204.

27) Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148(10): 1301-8.

28) Heresco-Levy U, Silipo G, Javitt DC. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996; 32(4): 731-40.

29) Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995; 13(4): 335-45.

30) Catts SV, Ward PB, Lloyd A, Huang XF, Dixon G, Chahl L y col. Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. Aust N Z J Psychiatry 1997; 31(1): 17-26.

31) Hirsch SR, Das I, Garey LJ, de Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 1997; 56(4): 797-802.

32) Thornberg SA, Saklad SR. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 1996;16(1): 82-93.

33) Cunniffe JG, Whitby-Strevens S, Wilcox MH. Effect of pH changes in cerebrospinal fluid specimens on bacterial survival and antigen test results. J Clin Pathol 1996;49: 249-253.

34) Hart G. Cerebrospinal Fluid. Melbourne: University of Melbourne, 1996.

35) Lee J, Taira T, Pihlaja P, Ransom BR, Kaila K. Effects of CO2 on excitatory transmission apparently caused by changes in intracellular pH in the rat hippocampal slice. Brain Res 1996; 706(2): 210-6.

36) Bullock J. Acid-base physiology. En: Bullock J, Boyle J, Wang M. Physiology. Baltimore: Williams & Wilkins, 2nd ed., 1991.

37) Filley G F. Acid-base and blood gas regulation. Philadelphia: Lea & Febiger, 1971.

38) Kashiwagi K, Fukuchi J, Chao J, Igarashi K, Williams K. An aspartate residue in the extracellular loop of the N-methyl-D-aspartate receptor controls sensitivity to spermine and protons. Mol Pharmacol 1996;49(6): 1131-41.

39) Kashiwagi K, Pahk AJ, Masuko T, Igarashi K, Williams K. Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol 1997;52(4): 701-13.

40) Pahk AJ, Williams K. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett 1997;225(1): 29-32.

41) Lembreghts M, Ansseau M. Les marqueurs biologiques dans les schizophrénies. L’éncéphale 1993;19: 501-23.

42) Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991;121: 77-80.

43) Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE y col. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52: 258-266.

44) Quirion R, Bayorh MS, Zerbe RL, Pert CV. Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides 1984; 5: 967-73.

45) Zukin SR, Zukin RS, Vale W. An endogenous ligand of the brain s/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res 1987; 415: 84-89.

46) Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 1993; 92(1): 57-65.

47) Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. Arch Gen Psychiatry 1994;51: 199-214.

48) Tamminga CA, Holcomb HH, Gao XM, Lahti AC. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995;10(Suppl 3): 29-37.

49) Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of Ketamine-Induced Psychosis With Focal Activation of the Prefrontal Cortex in Healthy Volunteers. Am J Psychiatry 1997;154(6): 805-11.

50) Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52(12): 998-1007.

51) Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St. Peter H, Olney JW. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol Psychiatry 1995; 38(12): 788-96.

52) Teitz NW. Clinical Guide to Laboratory Tests. W.B. Saunders Co, 1983Young AB, Dauth GW, Hollingsworth Z, Penney JB, Katz K, Gilman S. Quisqualate- and NMDA-sensitive [sup 3 H] glutamate binding in primate brain. J Neurosci Res 1990;27: 512-521.

53) Morris ME. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnesium Res 1992; 5(4): 303 – 13.

54) Altura BT, Altura BM. Interactions of Mg and K on cerebral vessels—aspects in view of stroke. Review of present status and new findings. Magnesium 1984; 3(4-6): 195-211.

55) Sims MH, Bell MC, Ramsey N. Electrodiagnostic evaluation of hypomagnesemia in sheep. J Anim Science 1980;50(3): 539-46.

56) Fuchs-Buder T, Tramer MR, Tassonyi E. Cerebrospinal fluid passage of intravenous magnesium sulfate in Neurosurgical patients. J Neurosurg Anesth 1997; 9(4): 324-8.

57) Meyer JG, Urban K. Electrolyte changes and acid base balance after alcohol withdrawal, with special reference to rum fits and magnesium depletion. J Neurol 1997; 215(2): 135-40.

58) Kramp P, Hemmingsen R, Rafaelsen OJ. Magnesium concentrations in blood and cerebrospinal fluid during delirium tremens. Psych Res 1979; 1(2): 161-71.

59) Reed DJ, Yen MH. The role of the cat choroid plexus in regulating cerebrospinal fluid magnesium. J Physiol (Lond) 1978; 281: 477-85.

60) Seelig JM, Wei EP, Kontos HA, Choi SC, Becker DP. Effect of changes in magnesium ion concentration on cat cerebral arterioles. Am J Physiol 1983; 245(1): H22-6.

61) Buck DR, Mahoney AW, Hendricks DG, Effect of Mg deficien-cy on nonspecific excitability level (NEL) and audiogenic seizure susceptibility. Pharm Biochemist & Behavior 1976; 5: 529-34.

62) Banki CM, Vojnik M, Papp Z, Balla KZ, Arato M. Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts. Biol Psych 1985; 20(2): 163-71.

63) Banki CM, Arato M, Kilts CD. Aminergic studies and cerebrospinal fluid cations in suicide. Ann New York Acad Scien 1986; 487: 221-30.

64) Penney JB. Neurochemical neuroanatomy. En: Fogel BS, Schiffer RB, Rao SM. Neuropsychiatry. Baltimore: Williams & Wilkins, 1996; 8: 145-71.

65) Levine J, Rapoport A, Mashiah M, Dolev E. Serum and cerebrospinal levels of calcium and magnesium in acute versus remitted schizophrenic patients. Neuropsychobiology 1996; 33(4): 169-72.

Regresar